4164 Chengye Medical: Subsidiary Fukang Active Pharma Announces Cash Capital Increase via New Share Issuance
Key facts
- 4164 Chengye Medical: Subsidiary Fukang Active Pharma Announces Cash Capital Increase via New Share Issuance
- Chengye Medical's key subsidiary, Fukang Active Pharmaceutical Co., Ltd., has announced a cash capital increase through the issuance of new shares to strengthen operational funding. A total of 880,300 ordinary shares will be issued at NT$88 per share, raising approximately NT$77.47 million.
- Source: PR Times
- Date: June 27, 2026
Direct answer
Chengye Medical's key subsidiary, Fukang Active Pharmaceutical Co., Ltd., has announced a cash capital increase through the issuance of new shares to strengthen operational funding. A total of 880,300 ordinary shares will be issued at NT$88 per share, raising approximately NT$77.47 million.
- Citation
- 4164 Chengye Medical: Subsidiary Fukang Active Pharma Announces Cash Capital Increase via New Share Issuance (June 27, 2026), PR Times
- Source
- PR Times
- Date
- June 27, 2026
Chengye Medical's key subsidiary, Fukang Active Pharmaceutical Co., Ltd., has announced a cash capital increase through the issuance of new shares to strengthen operational funding. A total of 880,300 ordinary shares will be issued at NT$88 per share, raising approximately NT$77.47 million.
📋 Article Processing Timeline
- 📰 Published: June 27, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 15:23 (6h 23m after Published)
- 🤖 AI Analyzed: June 27, 2026 at 15:26 (2 min after Collected)
Announcement Date: June 27, 2026
Statement Date: June 26, 2026
Statement Time: 16:25:53
Company Code: 4164
Company Name: Chengye Medical
Subject: Announcement by important subsidiary Fukang Active Pharmaceutical Co., Ltd. of board resolution on cash capital increase via new share issuance
Applicable Clause: Clause 11
Factual Date: June 26, 2026
Details:
1. Board resolution date: June 26, 2026 (115/06/26)
2. Source of capital increase: Cash issuance of new shares
3. Use of blanket declaration for new share issuance (Yes, specify planned issuance period / No): No
4. Total issuance amount and number of shares (excluding employee allocation for retained earnings or reserve capital increases): NT$77,466,400, 880,300 ordinary shares
5. Issuance amount and number of shares for blanket declaration cases: Not applicable
6. Remaining amount and share balance after this issuance under blanket declaration: Not applicable
7. Par value per share: NT$10
8. Issuance price: NT$88
9. Number of shares subscribed by employees or allocated amount: 88,030 shares
10. Public offering number of shares: Not applicable
11. Subscription or free allocation ratio for existing shareholders: 90%
12. Handling method for fractional shares and unclaimed shares: Authorized Chairman to arrange subscription by specific persons
13. Rights and obligations of the newly issued shares: Same rights and obligations as existing shares
14. Use of capital increase funds: To strengthen operational capital
15. Rationality and necessity of fundraising after cash reduction (applicable if cash reduction was conducted in the current or previous year): Not applicable
16. Other matters to be stated: None
Statement Date: June 26, 2026
Statement Time: 16:25:53
Company Code: 4164
Company Name: Chengye Medical
Subject: Announcement by important subsidiary Fukang Active Pharmaceutical Co., Ltd. of board resolution on cash capital increase via new share issuance
Applicable Clause: Clause 11
Factual Date: June 26, 2026
Details:
1. Board resolution date: June 26, 2026 (115/06/26)
2. Source of capital increase: Cash issuance of new shares
3. Use of blanket declaration for new share issuance (Yes, specify planned issuance period / No): No
4. Total issuance amount and number of shares (excluding employee allocation for retained earnings or reserve capital increases): NT$77,466,400, 880,300 ordinary shares
5. Issuance amount and number of shares for blanket declaration cases: Not applicable
6. Remaining amount and share balance after this issuance under blanket declaration: Not applicable
7. Par value per share: NT$10
8. Issuance price: NT$88
9. Number of shares subscribed by employees or allocated amount: 88,030 shares
10. Public offering number of shares: Not applicable
11. Subscription or free allocation ratio for existing shareholders: 90%
12. Handling method for fractional shares and unclaimed shares: Authorized Chairman to arrange subscription by specific persons
13. Rights and obligations of the newly issued shares: Same rights and obligations as existing shares
14. Use of capital increase funds: To strengthen operational capital
15. Rationality and necessity of fundraising after cash reduction (applicable if cash reduction was conducted in the current or previous year): Not applicable
16. Other matters to be stated: None
FAQ
How will this capital increase affect the stock price?
Short-term dilution possible, but long-term operational improvements may positively impact share value.
What is Fukang Active Pharma's core business?
Develops, manufactures, and sells prescription pharmaceuticals, specializing in chronic disease treatments.
Is the use of funds clearly defined?
Yes, the press release clearly states 'to strengthen operational capital,' indicating high transparency.